Additional Positive Interim Data from Phase I/II Trial of REGENXBIO'S RGX-111 for the Treatment of Severe MPS I Presented at WORLDSymposium™
REGENXBIO (RGNX) announced positive interim data for RGX-111, a one-time gene therapy targeting severe Mucopolysaccharidosis Type I (MPS I), at the WORLD Symposium. The Phase I/II trial shows RGX-111 is well-tolerated with no serious adverse events. Key findings include positive CNS biomarker activity and encouraging neurodevelopmental gains among participants. RGX-111 is designed to deliver the IDUA gene via AAV9 vector, aiming for long-term treatment effects. The company expects to manufacture commercial-scale material for further clinical development in 2023, aligning with its '5x'25 strategy to advance multiple gene therapies.
- RGX-111 shows no drug-related serious adverse events in Phase I/II trial.
- Encouraging CNS biomarker activity suggests therapeutic efficacy.
- Neurodevelopmental improvements observed in trial patients.
- Company on track for production of commercial-scale material in 2023.
- None.
- RGX-111 is an investigational AAV Therapeutic for the treatment of severe MPS I that is part of
REGENXBIO's clinical-stage pipeline of neurodegenerative disease programs - RGX-111, a potential one-time gene therapy for MPS I, continues to be well-tolerated across two dose levels, with no drug-related serious adverse events
- New biomarker and neurodevelopmental data continue to indicate encouraging CNS profile in patients dosed with RGX-111
- Company is on track to manufacture commercial-scale cGMP material to support the continued development of RGX-111
"RGX-111 is our second-most advanced clinical candidate in our neurodegenerative disease pipeline and is part of our '5x'25' strategy to have five gene therapies either on the market or in late-stage development by 2025. We are encouraged to see that this potential one-time gene therapy using our NAV AAV9 vector continues to demonstrate compelling evidence of CNS biomarker activity," said
"There is a great need for new treatment options that provide lasting expression of the IDUA enzyme and the reduction of glycosaminoglycans in the central nervous system," said
RGX-111 is an investigational one-time gene therapy designed to deliver the gene that encodes the IDUA enzyme using the AAV9 vector. RGX-111 is administered directly to the central nervous system (CNS). The primary endpoint of the trial is to evaluate the safety of RGX-111. Secondary and exploratory endpoints include biomarkers of IDUA enzyme activity in the cerebrospinal fluid (CSF), serum and urine, neurodevelopmental assessments, and caregiver reported outcomes. Patients were treated across two dose cohorts: 1.0x1010 genome copies per gram (GC/g) of brain mass (n=2) and 5.0x1010 GC/g of brain mass (n=6). In the single-patient IND for RGX-111, a severe MPS I patient was dosed with 1x1010 GC/g of brain mass.
Data Summary and Safety Data
As of
RGX-111 continued to be well-tolerated in the single-patient IND with no drug-related SAEs as of
CSF Biomarker Data
Data from patients in the Phase I/II trial and the single-patient IND indicate positive IDUA biomarker activity in the CNS following one-time administration of RGX-111. Heparan sulfate (HS) is a glycosaminoglycan (GAG) that is a key biomarker of IDUA enzyme activity. In the Phase I/II trial, a decrease in CSF HS was observed through the last timepoint available in the majority of patients following administration of RGX-111. Measurable CSF IDUA enzyme activity was detected after RGX-111 administration in four of the five Phase I/II trial patients and in the single patient IND participant.
Neurodevelopmental Data
Patients in the Phase I/II trial and the single-patient IND demonstrated encouraging continued neurodevelopmental skill acquisition, as measured by age and developmentally appropriate validated instruments for neurodevelopmental testing, including the Bayley Scales of
All five patients assessed with BSID-III demonstrated continued developmental skill acquisition on all subsets (cognition, expressive language and fine motor). At the last assessment, four of the five patients had function ≥ -2 standard deviations of the normative mean on the cognition, expressive language and fine motor subtests. Cognitive function in a Phase I/II trial patient and the single IND patient was higher than the age equivalent scores in the available natural history data.
One patient in Cohort 1 who entered the trial at 13 years old demonstrated neurodevelopmental improvements as measured by the WASI-II and showed improvement in the majority of subdomains of the VABS-III at approximately 18 months after RGX-111 administration.
Systemic Biomarker Data
Evidence of systemic biomarker activity was observed in patients in both cohorts of the Phase I/II trial and the single-patient IND. Patients who had elevated baseline levels of I0S6 in plasma, a key biomarker of IDUA enzyme activity in MPS I patients, demonstrated decreases in I0S6 levels following administration of RGX-111. In addition, the majority patients dosed with RGX-111 maintained low levels of total urine GAGs at the last timepoint available.
The study findings presented at the WORLDSymposium are available under the Presentations & Publications page in the Media section of the company's website, located at www.regenxbio.com.
About RGX-111
RGX-111 is designed to use the AAV9 vector to deliver the α-l-iduronidase (IDUA) gene to the central nervous system (CNS). Delivery of the IDUA gene within the cells in the central nervous system (CNS) could provide a permanent source of secreted IDUA beyond the blood-brain barrier, allowing for long-term cross-correction of cells throughout the CNS. By providing rapid IDUA delivery to the brain, RGX-111 could potentially help prevent the progression of cognitive deficits that otherwise occurs in MPS I patients. RGX-111 has received orphan drug product, rare pediatric disease and Fast Track designations from the
About Mucopolysaccharidosis Type I (MPS I)
MPS I is a rare autosomal recessive genetic disease caused by a deficiency in the lysosomal enzyme alpha-L-iduronidase (IDUA), leading to an accumulation of glycosaminoglycans (GAGs) including heparan sulfate (HS) in tissues which ultimately results in cell, tissue, and organ dysfunction, including in the central nervous system (CNS). This can include excessive accumulation of fluid in the brain, spinal cord compression, and cognitive impairment. MPS I is estimated to occur in 1 in 100,000 births. Current disease modifying therapies for MPS I include hematopoietic stem cell transplant (HSCT) and enzyme replacement therapy with a recombinant form of human IDUA administered intravenously. However, intravenous enzyme therapy does not treat the CNS manifestations of MPS I, and HSCT can be associated with clinically significant morbidity and mortality. Key biomarkers of IDUA enzymatic activity in MPS I patients include its substrate heparan sulfate (HS), which has been shown to correlate with neurocognitive manifestations of the disorder.
About REGENXBIO Inc.
Forward-Looking Statements
This press release includes "forward-looking statements," within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements express a belief, expectation or intention and are generally accompanied by words that convey projected future events or outcomes such as "believe," "may," "will," "estimate," "continue," "anticipate," "assume," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would" or by variations of such words or by similar expressions. The forward-looking statements include statements relating to, among other things,
Contacts:
Corporate Communications
dcormack@regenxbio.com
Investors:
ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/additional-positive-interim-data-from-phase-iii-trial-of-regenxbios-rgx-111-for-the-treatment-of-severe-mps-i-presented-at-worldsymposium-301755222.html
SOURCE
FAQ
What are the results from REGENXBIO's RGX-111 trial presented on February 24, 2023?
What is RGX-111 and its significance for MPS I treatment?
What regulatory designations has RGX-111 received?
When does REGENXBIO plan to produce RGX-111 at commercial scale?